Indivior Upsizes $450M Convertible Notes Offering, Eyes Debt Repayment and Share Buybacks
Event summary
- Indivior priced a $450M upsized offering of 0.625% convertible senior notes due 2031, up from $400M.
- Notes carry an initial conversion price of ~$41.66 per share, a 35% premium over the last reported stock price.
- Proceeds (~$437.7M) will repay $239M in borrowings, repurchase ~2.4M shares (~$75M), and fund general corporate purposes.
- Initial purchasers have a 30-day option to buy an additional $50M in notes.
The big picture
Indivior's upsized convertible notes offering reflects a strategic pivot to strengthen its balance sheet and return capital to shareholders. The move aligns with broader trends in the pharmaceutical sector, where companies are optimizing capital structures to navigate regulatory and market uncertainties. The $450M deal underscores Indivior's focus on debt repayment and shareholder value, signaling confidence in its long-term financial strategy.
What we're watching
- Debt Management
- Whether Indivior can sustain its debt reduction strategy amid fluctuating market conditions.
- Shareholder Returns
- How the $75M share buyback will impact stock price and investor sentiment.
- Market Conditions
- The pace at which Indivior can convert notes to shares without destabilizing its stock.
Related topics